The second axis of Cerebrospinal Fluid Testing Service segmentation categorises the market by type of analysis, each generating distinct cost structures and volume profiles. Biochemical analysis—including enzyme assays, protein electrophoresis, and metabolite quantification—captures the largest share, roughly 45 % of service revenue, because routine panels are ordered for a wide spectrum of neurological conditions. Cytology, which encompasses cell count, differential, and immunocytochemistry, accounts for about 25 % and is essential for detecting malignant cells or inflammatory patterns, driving higher per‑test fees. Microbiology—covering Gram stain, culture, and antigen detection—contributes near 20 % as acute meningitis work‑ups require rapid pathogen identification. Molecular diagnostics, comprising PCR, multiplex panels, and next‑generation sequencing, holds the remaining 10 % but exhibits the fastest growth, projected at 12 % CAGR, reflecting increasing adoption of pathogen‑specific and mutation‑targeted assays. Collectively, these type segments define the market’s pricing hierarchy and forecasted expansion, enabling analysts to allocate resources according to procedural complexity and reimbursement dynamics.